Thailand Adopts Policy To Restrict Use Of A/H1N1 Antivirals
This article was originally published in PharmAsia News
Executive SummaryThailand's Public Health Ministry has put in place plans to impose restrictions on the use of antiviral drugs for treating the A/H1N1 flu virus. The restrictions are intended to avoid the virus developing into a drug-resistant version as a result of over-prescribing. Under the plan, the drugs are to be prescribed only after laboratory tests confirm a patient has A/H1N1. Until the new guidelines, the ministry had allowed Roche's Tamiflu (oseltamivir) to be provided to patients who had a high fever and had recently returned from countries where infections were reported. (Click here for more
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.